enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
enVVeno Medical (Nasdaq: NVNO) announced that CEO Robert Berman will participate in a Virtual Investor Closing Bell event on June 9, 2026, at 4:00 PM ET.
enVVeno Medical (Nasdaq: NVNO) announced that CEO Robert Berman will participate in a Virtual Investor Closing Bell event on June 9, 2026, at 4:00 PM ET.
He will discuss the recently reported FDA IDE approval for the enVVe System and host a live Q&A, with webcast and 90-day replay on the company website.
On Jun 2, the day this news came out, NVNO closed 0.72% above the previous close.
Data tracked by StockTitan Argus for the Jun 2 session.
Market Context
This announcement highlights enVVeno’s continued investor outreach via a Virtual Investor Closing Be...
Analysis
This announcement highlights enVVeno’s continued investor outreach via a Virtual Investor Closing Bell event, where the CEO will discuss the recently reported FDA IDE approval for a U.S. pivotal study of the enVVe System. In recent months, the company has emphasized cash balances of about $24.9M–$28.2M and runway into Q3 2027. Investors may focus on trial timelines, expected cash burn of $4–5M per quarter, and how the pivotal study design is communicated.
Key Figures
Cash & investments:$24.9MCash runway:into Q3 2027Addressable patients:3 million+5 more
Cash & investments
$24.9M
As of March 31, 2026 (Q1 2026 results)
Cash runway
into Q3 2027
Guidance from Q1 2026 update
Addressable patients
3 million
U.S. patients with severe deep CVI cited for enVVe
Regained Nasdaq minimum bid price compliance and reiterated cash of about $28M.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ide approval, fda ide, pivotal study, venous valve, +1 more
5 terms
ide approvalregulatory
"recently reported IDE approval of its enVVe® System, marking a first-ever FDA IDE approval"
IDE approval is authorization from the U.S. regulator allowing a company to test a medical device in human clinical trials under an Investigational Device Exemption. It matters to investors because it is a formal regulatory green light to gather the safety and performance data required for eventual market clearance or approval; like getting a building permit to test a new design, it unlocks a critical development phase, affects timelines, costs, and the project’s risk profile.
fda ideregulatory
"marking a first-ever FDA IDE approval for a U.S. pivotal study"
An FDA IDE (Investigational Device Exemption) is official permission from the U.S. regulator to test a medical device in people when the device isn’t yet approved for general use. For investors, an IDE is like a green light to run the critical human tests that can prove a device works and is safe; receiving one reduces regulatory uncertainty and can be a key milestone that increases a project’s value and clarity about potential approval timelines.
pivotal studymedical
"first-ever FDA IDE approval for a U.S. pivotal study of a non-surgical replacement venous valve"
A pivotal study is a large, definitive clinical trial designed to show whether a medical product works and is safe enough for regulators to approve and for doctors to use. Think of it as the final exam that determines whether a drug or device moves from testing into the market; its results can dramatically change a company’s approval chances, future sales prospects, and therefore its stock value.
venous valvemedical
"pivotal study of a non-surgical replacement venous valve"
A venous valve is a small, one-way flap inside a vein that keeps blood flowing toward the heart and prevents it from pooling or running backward, like a check valve in a plumbing pipe. For investors, venous valve health matters because damage or failure drives demand for treatments, devices and diagnostic tests, influences clinical trial activity and regulatory decisions, and can affect companies focused on vascular care and related markets.
webcasttechnical
"A live video webcast will be available on the Events page of the Company's website"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Virtual Investor Closing Bell event on Tuesday, June 9, 2026 at 4:00 PM ET.
As part of the event, Mr. Berman will discuss the Company's recently reported IDE approval of its enVVe® System, marking a first-ever FDA IDE approval for a U.S. pivotal study of a non-surgical replacement venous valve.
Additionally, there will be a live question and answer session with audience participants. Mr. Berman will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will become available two hours following the live event and will be accessible for 90 days.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is currently developing the enVVe system, which includes a first-in-class non-surgical replacement venous valve being developed for the treatment of severe Deep Venous Insufficiency (DVI). The enVVe valve is designed to act as one-way valve, to help assist in propelling blood up the leg, and back to the heart and lungs. As a transcatheter delivered device, the enVVe procedure will be performed under light sedation and should not require an over-night hospital stay.
INVESTOR CONTACT:
JTC Team, LLC Jenene Thomas NVNO@jtcir.com (908) 824-0775
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is enVVeno Medical (NVNO) presenting at the Virtual Investor Closing Bell event?
enVVeno Medical will present at the Virtual Investor Closing Bell event on June 9, 2026, at 4:00 PM ET. According to enVVeno, CEO Robert Berman will speak and answer investor questions during a live video webcast.
What will enVVeno Medical CEO discuss at the June 9, 2026 Virtual Investor Closing Bell event?
Robert Berman will discuss enVVeno Medical's recently reported IDE approval for its enVVe System. According to enVVeno, this IDE marks the first FDA IDE approval for a U.S. pivotal study of a non-surgical replacement venous valve and will be a key topic.
How can investors watch enVVeno Medical's June 9, 2026 Virtual Investor Closing Bell webcast?
Investors can watch the live webcast on the Events page of enVVeno Medical's website. According to enVVeno, the live video stream will start at 4:00 PM ET and will include a presentation plus an interactive Q&A session.
Will there be a replay of enVVeno Medical's Virtual Investor Closing Bell event for NVNO investors?
Yes, a replay of the Virtual Investor Closing Bell webcast will be available. According to enVVeno, the replay will become accessible about two hours after the live event and will remain available on the company's website for 90 days.
Will enVVeno Medical's June 9, 2026 Virtual Investor event include a Q&A session?
Yes, the event will feature a live question and answer session with participants. According to enVVeno, Robert Berman will answer as many audience questions as possible within the allotted time during the Virtual Investor Closing Bell webcast.
